Verve Therapeutics (NASDAQ:VERV) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Verve Therapeutics (NASDAQ:VERV – Free Report) from a sell rating to a hold rating in a research report report published on Thursday. Several other brokerages also recently issued reports on VERV. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.00 to $15.00 and set an […]
Wall Street Zen upgraded shares of Verve Therapeutics (NASDAQ:VERV – Free Report) from a sell rating to a hold rating in a research report report published on Thursday. Several other brokerages also recently issued reports on VERV. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.00 to $15.00 and set an […]
